Metagenomi

Today is #RareDiseaseDay, a time to recognize the more than 300 million people worldwide living with a rare disease. At Metagenomi, we are driven by a bold vision: to create curative genetic medicines for patients. We are inspired by the resilience of the rare disease community - patients, caregivers, and advocates - who push us to advance the science of gene editing. Together, we strive for a future where innovative therapies transform lives. Learn more about #RareDiseaseDay and how you can support the community: https://lnkd.in/e76yAESx

We’re pleased to share that our CEO & Founder, Brian C. Thomas, PhD, will take part in a fireside chat at TD Cowen’s 45th Annual Health Care Conference. The discussion will focus on Metagenomi’s pipeline and technology advancements as the company continues to progress its lead therapeutic programs toward the clinic.   Further details on the fireside chat and our participation at the conference can be found in our latest press release: https://lnkd.in/gGV4NgXE

Today, Metagenomi shared highlights on recent progress across our therapeutic portfolio and outlined anticipated milestones for 2025. Read the full update here: https://lnkd.in/gVV-Ewtw

We are pleased to announce that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi’s Board of Directors. Read the full announcement here: https://lnkd.in/g9udU7xg

Join us on Wednesday, January 15, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco for a presentation from our CEO and founder, Brian C. Thomas, PhD. Don't miss his talk at 4:30 p.m. PT where he will share insights into Metagenomi’s latest advancements and what’s ahead for the company in 2025. A live webcast will be available in the investor section of Metagenomi's website: https://lnkd.in/gEPHPKAK #JPM25 #Metagenomi #GeneEditing #JPM

This week in San Diego we were pleased to present our progress on two separate occasions - at ASH, where we shared our latest preclinical data in hemophilia A; and at Nature's "RNA at the bench and bedside IV," where we presented our highly specific and efficient genome editing tools. To learn more, see our latest press releases for updates from ASH and the Nature Conference "RNA at the bench and bedside IV." ASH: https://lnkd.in/g44m7gQn Nature Conference: https://lnkd.in/g53gCsfZ

Today, Metagenomi presented a novel compact base editing system, small enough to fit within the packaging limits of standard AAVs. These systems hold potential to broaden the therapeutic applications of genetic medicine, particularly in targeting neuromuscular disorders. Take a look at our poster titled “Engineering of compact and efficient adenine base editors from metagenomic derived systems” presented at the American Institute of Chemical Engineers (AIChE) 7th International Conference on CRISPR Technologies in San Diego, CA. Poster: https://lnkd.in/gmJZMrTP Press Release: https://lnkd.in/gGKRXjT6

Meeting on the Mesa attendees - Be sure to add our company presentation on Tuesday, October 8th, to your schedule! Join Metagenomi President & COO, Jian Irish, as she provides a company overview and highlights our latest innovations. #MeetingOnTheMesa Alliance for Regenerative Medicine

Metagenomi has announced that company management will participate in both a fireside chat and panel discussion at Chardan's 8th Annual Genetic Medicines Conference. For further details, please refer to the press release here: https://lnkd.in/gp78uNRZ

Metagenomi is excited to announce preclinical data for our lead program in hemophilia A, demonstrating durable factor VIII (FVIII) activity levels through twelve months of follow up. Hemophilia A is the most common X-linked inherited bleeding disorder, caused by a large variety of mutations in the FVIII gene leading to a loss of functional FVIII protein. Our goal is to provide a one-time, curative treatment for adults and children with hemophilia A. For further information, be sure to read the full press release linked below. Additionally, Metagenomi management will be holding a conference call tomorrow, September 4th at 8:30am EST. For login information, please visit Metagenomi's investor page on the Company website. Press Release: https://lnkd.in/g3XAnmgQ